MLYS vs. RXRX, XENE, AMRX, CPRX, HCM, BHC, NAMS, TWST, EWTX, and IBRX
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Bausch Health Companies (BHC), NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Edgewise Therapeutics (EWTX), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs.
Mineralys Therapeutics (NASDAQ:MLYS) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.
In the previous week, Mineralys Therapeutics had 4 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 13 mentions for Mineralys Therapeutics and 9 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.81 beat Mineralys Therapeutics' score of 0.80 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.
Mineralys Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Mineralys Therapeutics' return on equity of -67.97% beat Recursion Pharmaceuticals' return on equity.
Mineralys Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Mineralys Therapeutics currently has a consensus price target of $27.00, suggesting a potential upside of 66.98%. Recursion Pharmaceuticals has a consensus price target of $8.25, suggesting a potential upside of 21.50%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Mineralys Therapeutics is more favorable than Recursion Pharmaceuticals.
Mineralys Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Recursion Pharmaceuticals received 12 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote.
Summary
Mineralys Therapeutics beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy MLYS Stock Free MLYS Stock Alerts